// App-Quantinova.ai

684 : MDM2 inhibition for non‐genotoxic activation of TP53 ‐ a novel strategy for the treatment of hepatocellular carcinoma (HCC)

Researchers

Presenter

  • Ahmed K. Mahdi

Principal Investigators

  • Huw D. Thomas

  • Steve Wedge

  • Ruchi Shukla

  • Helen Reeves

  • John Lunec

Medical Centers

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Department of pathology and forensic medicine, College of Medicie, Al‐Nahrain University, Baghdad, Iraq

  • Great North Childrens Hospital, Newcastle upon Tyne Hospitals Foundation Trust,Newcastle upon Tyne, United Kingdom

Locations

  • United Kingdom

  • Iraq

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Mouse double minute 2 homolog

  • p53

  • Tumor protein p53

Drug/Treatment

  • HDM 201

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved